^
Association details:
Biomarker:EGFR exon 21 mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P76.11 - Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC

Published date:
01/12/2021
Excerpt:
Advanced NSCLC patients harboring EGFR sensitive mutations (19DEL/L858R) after resistant to EGFR-TKIs and received anti-PD1/PD-L1 based treatment any lines were retrospectively analyzed...EGFR mutated NSCLC patients with short PFS to EGFR-TKIs conferred better response to following anti-PD-1/PD-L1 based immunotherapy.